| Literature DB >> 33481085 |
Hiroyuki Kawamori1, Akihide Konishi2,3, Toshiro Shinke1,4, Hirokuni Akahori5, Masaharu Ishihara5, Hiroaki Tsujita4, Hiromasa Otake1, Takayoshi Toba1, Shinsuke Nakano1, Kosuke Tanimura1, Yoshiro Tsukiyama6, Isao Nanba7, Yasumasa Kakei7, Takahiro Yasuda8, Takashi Omori7, Takashi Kubo9, Amane Kozuki10, Junya Shite10, Ken-Ichi Hirata1.
Abstract
Optical frequency domain imaging (OFDI) is a high-resolution intracoronary imaging modality with fast automated longitudinal pullback. We aimed to evaluate the ability of performing OFDI from the superficial femoral artery (SFA) to the below-knee (BK) artery. This clinical trial was a multi-center, single-arm, open-label study. The primary endpoint was to obtain a clear image of the intra-vascular lumen from the SFA to the BK artery, specifically > 270° visualization of the blood vessel lumen with > 16/21 cross sections. The proportion of the clear image (≥ 85%) was regarded as confirmatory of the ability of OFDI to visualize the vessel lumen. Overall, 20 patients were enrolled. The proportion of the primary endpoint was 90% (18/20), and the pre-specified criterion was successfully attained. The proportion of the clear image assessed by the operator was 100% (20/20), and an additional statistical analysis for the proportion of the visualization, > 270°, of the blood vessel lumen revealed a significantly higher cut-off value than that for the pre-specified criterion, 85% (p = 0.0315). There were three adverse events not related to OFDI. OFDI achieved acceptable visualization of the vessel lumen without any adverse event related to it. After regulatory approval based on the present study, OFDI will be available as a new option of endovascular imaging for peripheral artery diseases in daily practiceTrial registration: This study was registered in the Japanese Registry of Clinical Trials (jRCT 2052190025, https://jrct.niph.go.jp/latest-detail/jRCT2052190025 ).Entities:
Keywords: Endovascular imaging; Optical frequency domain imaging; Peripheral artery disease; Regulatory approval
Year: 2021 PMID: 33481085 DOI: 10.1007/s00380-020-01758-y
Source DB: PubMed Journal: Heart Vessels ISSN: 0910-8327 Impact factor: 2.037